|
43 Companies |
|
55 Products |
|
55 Products |
|
60 Mechanisms of Action |
|
1 Trial |
|
670 News |
|
| «12...234567891011121314 |
- Ibsrela (tenapanor) / Ardelyx, Kyowa Kirin, Knight Therap, deferitazole (SHP602) / Takeda
Enrollment change: Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload (clinicaltrials.gov) - Feb 7, 2012
P1b, N=20, Completed, Sponsor: FerroKin BioSciences, Inc.
N=16 --> 20
- varespladib (A-002) / Anthera Pharma, Ophirex
New P2 trial: IMPACTS-2: A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (clinicaltrials.gov) - Jan 29, 2012
P2, N=2, Terminated, Sponsor: Anthera Pharmaceuticals
- New P2 trial: Effectiveness of Laying-on-of-hands for Sickle Cell Disease (clinicaltrials.gov) - Jan 20, 2012
P2, N=40, Completed, Sponsor: MOA Health Science Foundation
- | varespladib (A-002) / Anthera Pharma, Ophirex
Enrollment change: IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (clinicaltrials.gov) - Jan 17, 2012
P2, N=30, Completed, Sponsor: Anthera Pharmaceuticals
N=16 --> 20 N=60 --> 30
- hydroxyurea / Generic mfg.
New P1 trial: Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia (clinicaltrials.gov) - Jan 8, 2012
P1, N=40, Recruiting, Sponsor: Children's Mercy Hospital Kansas City
- Instanyl (fentanyl) / Takeda
Enrollment open: Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis (clinicaltrials.gov) - Dec 14, 2011
P4, N=200, Recruiting, Sponsor: Montefiore Medical Center
N=60 --> 30 Not yet recruiting --> Recruiting
- |||| deferasirox tablet for oral suspension / Generic mfg.
Trial completion: This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. (clinicaltrials.gov) - Nov 30, 2011
P4, N=111, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Instanyl (fentanyl) / Takeda
New P4 trial: Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis (clinicaltrials.gov) - Nov 28, 2011
P4, N=200, Recruiting, Sponsor: Montefiore Medical Center
- | prasugrel / Generic mfg.
New P2 trial: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (clinicaltrials.gov) - Nov 20, 2011
P2, N=33, Completed, Sponsor: Eli Lilly and Company
- | Enrollment change: Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec (clinicaltrials.gov) - Nov 14, 2011
P2, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=50 --> 20
- | Trial completion: Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec (clinicaltrials.gov) - Nov 14, 2011
P2, N=20, Completed, Sponsor: Novartis Pharmaceuticals
N=50 --> 20 Recruiting --> Completed
- zoledronic acid / Generic mfg.
Trial withdrawal: Phase 1 Study of Zoledronic Acid in Sickle Cell Disease (clinicaltrials.gov) - Nov 9, 2011
P1/2, N=0, Withdrawn, Sponsor: Virginia Commonwealth University
Recruiting --> Completed Terminated --> Withdrawn
- Enrollment change, IO biomarker: A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension (clinicaltrials.gov) - Nov 3, 2011
P2, N=0, Withdrawn, Sponsor: University of North Carolina, Chapel Hill
Terminated --> Withdrawn N=20 --> 0
- | prasugrel / Generic mfg.
Trial completion: A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet (clinicaltrials.gov) - Oct 13, 2011
P1, N=18, Completed, Sponsor: Eli Lilly and Company
N=20 --> 0 Active, not recruiting --> Completed
- Enrollment open: CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant (clinicaltrials.gov) - Sep 22, 2011
P2, N=35, Recruiting, Sponsor: New York Medical College
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| deferasirox tablet for oral suspension / Generic mfg.
Trial completion: Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload (clinicaltrials.gov) - Sep 8, 2011
P4, N=309, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | prasugrel / Generic mfg.
New P1 trial: A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet (clinicaltrials.gov) - Sep 5, 2011
P1, N=18, Completed, Sponsor: Eli Lilly and Company
- | amlodipine besilate / Generic mfg.
Enrollment open: AmloThal: Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major (clinicaltrials.gov) - Aug 25, 2011
P3, N=60, Recruiting, Sponsor: University of Campinas, Brazil
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Trial completion: THALASSA: Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study (clinicaltrials.gov) - Aug 25, 2011
P2, N=166, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion, Adverse events: Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=100, Completed, Sponsor: HaEmek Medical Center, Israel
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=50, Completed, Sponsor: HaEmek Medical Center, Israel
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=60, Completed, Sponsor: HaEmek Medical Center, Israel
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=50, Completed, Sponsor: HaEmek Medical Center, Israel
Recruiting --> Completed Not yet recruiting --> Completed
- Trial completion: Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia (clinicaltrials.gov) - Aug 24, 2011
P=N/A, N=50, Completed, Sponsor: HaEmek Medical Center, Israel
Not yet recruiting --> Completed Recruiting --> Completed
- | Fragmin (dalteparin sodium) / Pfizer, Eisai
New P2 trial: Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo (clinicaltrials.gov) - Aug 17, 2011
P2, N=34, Active, not recruiting, Sponsor: Duke University
- Enrollment open: ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician? (clinicaltrials.gov) - Aug 15, 2011
P=N/A, N=100, Recruiting, Sponsor: Wolfson Medical Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change, Biopsy: Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=7, Terminated, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=12 --> 7